EFFECTIVENESS OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS: A COMBINED ANALYSIS OF REAL-WORLD EVIDENCE

被引：0
作者：
Cummings, Fraser
Buisson, Anthony
Smith, Philip J.
Rahmany, Sohail
Subramanian, Sreedhar
Kwon, Buki
Park, Soyeon
Lee, Young Nam
Fumery, Mathurin
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1854
引用
收藏
页码：S1144 / S1144
页数：1
相关论文
共 50 条
[41]   Comparison of discontinuation/switching between infliximab biosimilar and originator among Inflammatory Bowel Disease patients: a real-world analysis of two Canadian cohorts [J].
Moura, C. S. ;
Lukusa, L. ;
Wong, E. C. ;
Lakatos, P. L. ;
Afif, W. ;
Narula, N. ;
Bernatsky, S. .
JOURNAL OF CROHNS & COLITIS, 2022, 16 :I293-I293
[42]   Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis [J].
Kumar, Peeyush ;
Vuyyuru, Sudheer K. ;
Kante, Bhaskar ;
Kedia, Saurabh ;
Sahu, Pabitra ;
Ranjan, Mukesh Kumar ;
Mundhra, Sandeep ;
Golla, Rithvik ;
Kumar, Mukesh ;
Virmani, Shubi ;
Gupta, Anvita ;
Yadav, Nidhi ;
Makharia, Govind ;
Ahuja, Vineet .
INDIAN JOURNAL OF GASTROENTEROLOGY, 2022, 41 (05) :446-455
[43]   Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis [J].
Peeyush Kumar ;
Sudheer K. Vuyyuru ;
Bhaskar Kante ;
Saurabh Kedia ;
Pabitra Sahu ;
Mukesh Kumar Ranjan ;
Sandeep Mundhra ;
Rithvik Golla ;
Mukesh Kumar ;
Shubi Virmani ;
Anvita Gupta ;
Nidhi Yadav ;
Govind Makharia ;
Vineet Ahuja .
Indian Journal of Gastroenterology, 2022, 41 :446-455
[44]   Real-life experiences of switching from intravenous to subcutaneous vedolizumab maintenance therapy in patients with inflammatory bowel disease [J].
Kolehmainen, Sara ;
Rautakorpi, Jaakko ;
Loyttyniemi, Eliisa ;
Af Bjorkesten, Clas-Goeran ;
Arkkila, Perttu ;
Salminen, Kimmo ;
Sipponen, Taina .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 36 (10) :1193-1201
[45]   Effect on direct and indirect costs of switching Inflammatory Bowel Disease patients from intravenous to subcutaneous infliximab (CT-P13) [J].
Carbery, I. ;
Broglio, G. ;
Clark, T. ;
Greer, D. ;
Alakkari, A. ;
Selinger, C. P. .
JOURNAL OF CROHNS & COLITIS, 2023, 17 :861-861
[46]   Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13) [J].
Carbery, Isabel ;
Burdge, Gemma ;
Clark, Tanya ;
Broglio, Giacomo ;
Greer, Dan ;
Alakkari, Alaa ;
Selinger, Christian Philipp .
BMJ OPEN GASTROENTEROLOGY, 2023, 10 (01)
[47]   Comment on "Switching to Subcutaneous Infliximab Maintenance Therapy is Effective in Patients with Inflammatory Bowel Disease" [J].
Borras-Blasco, Joaquin ;
Valcuende-Rosique, Alejandro ;
Cornejo, Silvia .
DIGESTIVE DISEASES AND SCIENCES, 2025, 70 (07) :2547-2548
[48]   BIOSIMILAR INFLIXIMAB SWITCHING IS NOT ASSOCIATED WITH ADVERSE OUTCOMES: A REAL-WORLD EFFECTIVENESS ANALYSES IN A NATIONAL COHORT OF US MILITARY VETERANS WITH INFLAMMATORY BOWEL DISEASE [J].
Hou, Jason K. ;
Pham, Codey ;
Sansgiry, Shubhada ;
Modi, Varsha ;
Waljee, Akbar K. .
GASTROENTEROLOGY, 2023, 164 (06) :S645-S646
[49]   Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study [J].
Buisson, A. ;
Nachury, M. ;
Bazoge, M. ;
Yzet, C. ;
Wils, P. ;
Dodel, M. ;
Coban, D. ;
Pereira, B. ;
Fumery, M. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (04) :526-534
[50]   Switching from Intravenous to Subcutaneous Biological Therapy for Inflammatory Bowel Disease Patients Remains a Challenge [J].
Richter, Vered ;
Cohen, Daniel L. ;
Kriger-Sharabi, Ofra ;
Zelnik Yovel, Dana ;
Kochen, Nadav ;
Broide, Efrat ;
Shirin, Haim .
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (05)
12345